TYRA-300 0.50 mg/kg

Phase 2

TTyra Biosciences, Inc

TYRA-300 0.50 mg/kg is one of 13 therapeutic programs targeting Achondroplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AchondroplasiaRecruiting

AchondroplasiaPhase 2

Recruiting

Competition

Competitive Landscape

22 competitors in Achondroplasia

#DrugCompanyPhaseTrials

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

1 2

BMN 333

BioMarin Pharmaceutical

Phase 3

6 3

Voxzogo

BioMarin Pharmaceutical

Phase 2

2 4

Truseltiq

HHelsinn Healthcare SA

Phase 2

1 5

TYRA-300

TTyra Biosciences, Inc

Phase 2

1 6

Yuviwel

Ascendis Pharma

Phase 2

2 7

SAR442501

Recifercept

2 9

Infigratinib /kg

QQED Therapeutics, a BridgeBio company

Phase 2

2 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Achondroplasia

NCT06842355

Clinical

Trials by Indication[1]

Achondroplasia1 trial

A Multicenter, Phase 2, Dose-Escalation/Dose-Expansion Study of TYRA-300 in Children With Achondroplasia With Open Growth Plates: BEACH301

Recruiting·TTyra Biosciences, Inc·Phase 2·NCT06842355·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TYRA-300 0.50 mg/kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TYRA-300 0.50 mg/kg. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tyra Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTyra Biosciences, Inc

TYRA-300 0.50 mg/kg

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Achondroplasia1 trial

References

Drug Info

Quick Facts

Related News